NICE now backs Mounjaro for people with type 2 diabetes
Around 180,000 people in England and Wales with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by the National Institute for Health and Care Excellence (NICE.
In a U-turn by the UK health technology assessor, Mounjaro (tirzepatide), developed by US pharma major Eli Lilly (NYSE: LLY), has been recommended in final draft guidance issued by the NICE for treating poorly controlled type 2 diabetes in adults alongside diet and exercise. In June this year, the NICE declined to approve the drug for use on the National Health Service (NHS).
According to research by Diabetes UK, more than five million people in the UK are living with diabetes. The charity estimates around 90% of people with diabetes have type 2.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze